Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CNMAU-8 by Clene for Amyotrophic Lateral Sclerosis: Likelihood of Approval
CNMAU-8 is under clinical development by Clene and currently in Phase III for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase...
CNMAU-8 by Clene for Relapsing Multiple Sclerosis (RMS): Likelihood of Approval
CNMAU-8 is under clinical development by Clene and currently in Phase III for Relapsing Multiple Sclerosis (RMS). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Clene's CNMAU-8?
CNMAU-8 is a small molecule commercialized by Clene, with a leading Phase III program in Relapsing Multiple Sclerosis (RMS). According...
CNMAU-8 by Clene for Secondary Progressive Multiple Sclerosis (SPMS): Likelihood of Approval
CNMAU-8 is under clinical development by Clene and currently in Phase II for Secondary Progressive Multiple Sclerosis (SPMS). According to...
CNMAU-8 by Clene for Primary Progressive Multiple Sclerosis (PPMS): Likelihood of Approval
CNMAU-8 is under clinical development by Clene and currently in Phase II for Primary Progressive Multiple Sclerosis (PPMS). According to...